Cardiology
Conference Coverage
EHR-based thromboembolism risk tool boosted prophylaxis
A thromboembolism risk calculator in a hospital’s EHR led to a significant rise in appropriate thromboprophylaxis and a drop in thromboembolic...
Conference Coverage
Dietary supplements hyped as LDL cholesterol lowering are a bust: SPORT
The list of supplements without effects on LDL in the placebo-controlled trial include commercial preparations of fish oil, cinnamon, garlic,...
From the Journals
‘Lucid dying’: EEG backs near-death experience during CPR
“Recalled experiences and brain wave changes may be the first signs of the so-called near-death experience.”
Conference Coverage
New trial suggests CV benefit with EPA: RESPECT-EPA
The open-label trial could add some support to findings from the REDUCE-IT study, which showed a reduction in cardiovascular events with high-dose...
Conference Coverage
Chinese herbal medicine may offer benefits in STEMI: CTS-AMI
Treatment with tongxinluo was tied to better outcomes out to 1 year, but observers say further data are needed to see how it may fit into STEMI...
Conference Coverage
Precision CAD testing shows 70% cut in composite risk at 1 year
A streamlined protocol for evaluating suspected stable chest pain substantially improved outcomes at 1 year in the PRECISE trial.
Conference Coverage
Avoid routine early ECMO in severe cardiogenic shock: ECMO-CS
Early ECMO in this setting is increasingly common, but it didn’t seem to improve outcomes in the trial, compared with a more conservative approach...
Conference Coverage
ISCHEMIA-EXTEND: Conservative stable CAD management holds up
The ISCHEMIA trial results showed equipoise between conservative and invasive management of stable CAD. Extended follow-up strengthened the...
Conference Coverage
Study sheds new light on RAS inhibitors’ role for advanced CKD
“The results of this trial will inform future clinical practice worldwide and guideline recommendations.”
Conference Coverage
CRISPR gene editing takes next step in TTR amyloidosis
A phase 1 study showed robust responses in patients with TTR amyloidosis with cardiomyopathy, similar to those reported last year in amyloid...
Conference Coverage
No survival advantage for either torsemide or furosemide in HF: TRANSFORM-HF
One loop diuretic is the most widely used in heart failure, the other may have advantages in some situations, but there’s been no head-to-head...